MedTrace Logo

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

NCT03952572 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2019-05-16

No results posted yet for this study

Summary

Primary objective of the study is to compare the efficacy and safety of CDOP versus CHOP for newly diagnosed peripheral T-cell lymphoma (PTCL).

Conditions

  • Peripheral T-cell Lymphoma

Interventions

DRUG

Cyclophosphamide

750mg/m² ivgtt on day 1

DRUG

pegylated liposomal doxorubicin

40mg/m² ivgtt on day 1

DRUG

Vincristine

1.4mg/m²(Maximum 2 mg) ivgtt on day 1

DRUG

Prednisone

Prednisone100mg/m² po on day1-5

DRUG

Doxorubicin

50mg/m² ivgtt on day 1

Sponsors & Collaborators

  • Peking University

    lead OTHER

Principal Investigators

  • Jun Zhu, PHD · Peking University Cancer Hospital & Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-10
Primary Completion
2023-04-30
Completion
2023-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03952572 on ClinicalTrials.gov